IP Library › Granted Patent US 12,637,514
Granted Patent B2
US 12,637,514 · App. 18/844,737 · Granted May 26, 2026

Antibodies that inhibit erythropoietin receptor activation and methods of use thereof to treat cancer

Inventors: Bo Yu (Mountain View, CA); Edgar G. Engleman (Atherton, CA); Xiangyue Zhang (Sunnyvale, CA); David Kung-Chun Chiu (Mountain View, CA)
Assignees: ImmunEdge, Inc.; The Board of Trustees of the Leland Stanford University
C07K16/2866A61P37/02A61P37/06C07K14/505C07K16/22C12N15/113A61K2039/505C07K2317/31C07K2317/565C07K2317/70C07K2317/76C07K2319/30C07K2319/31C12N2310/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,637,514
App. No.
18/844,737
Granted
May 26, 2026
Kind
B2
Abstract

The present disclosure provides anti-EPOR antibodies, anti-EPO antibodies, and fragments thereof that specifically bind to the hetero-EPOR or homo-EPOR or EPO with high affinity. The anti-EPOR antibodies, anti-EPO antibodies, and/or engineered EPOs can be used to treat patients.

Claims (60)

1 . An antibody or an antigen binding fragment thereof, wherein said antibody or said antigen binding fragment thereof comprises:

(i) a VH complementarity determining region 1 (VH-CDR1), a VH-CDR2, and VH-CDR3 from SEQ ID NO: 1876 and a VL complementarity determining region 1 (VL-CDR1), a VL-CDR2, and a VL-CDR3 from SEQ ID NO: 1957, wherein said VL-CDR1, said VL-CDR2, said VL-CDR3, said VH-CDR1, said VH-CDR2, and said VH-CDR3 are defined according to Kabat, Chothia, IMGT, or AbM;

(ii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3342, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3478, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1337, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3614, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3750, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1473;

(iii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3403, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3539, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1398, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3675, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3811, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1534;

(iv) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2144, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2332, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 139, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2520, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2708, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 327,

(v) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3420, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3556, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1415, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3692, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3828, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1551; or

(vi) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3425, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3561, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1420, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3697, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3833, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1556.

2 . The antibody or an antigen binding fragment thereof of claim 1 ,

wherein said antibody or said antigen binding fragment thereof comprises:

(i) a VH-CDR1, a VH-CDR2, and VH-CDR3 from SEQ ID NO: 1876 and a VL-CDR1, a VL-CDR2, and a VL-CDR3 from SEQ ID NO: 1957, wherein said VH-CDR1, said VH-CDR2, said VH-CDR3, said VL-CDR1, said VL-CDR2, and said VL-CDR3 are defined according to Kabat, Chothia, IMGT, or AbM, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1876 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1957;

(ii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3342, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3478, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1337, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3614, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3750, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1473, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1609 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1745;

(iii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3403, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3539, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1398, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3675, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3811, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1534, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1670 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1806;

(iv) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2144, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2332, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 139, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2520, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2708, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 327, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 515 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 703;

(v) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3420, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3556, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1415, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3692, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3828, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1551, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1687 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1823; or

(vi) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3425, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3561, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1420, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3697, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3833, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1556, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1692 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1828.

3 . A method of increasing an immune response to a cancer of a subject in need thereof, the method comprising administering to said subject in need thereof a composition comprising an antibody or an antigen binding fragment thereof, wherein said antibody or said antigen binding fragment thereof inhibits erythropoietin receptor activation, and wherein said antibody or said antigen binding fragment thereof comprises:

(i) a VH complementarity determining region 1 (VH-CDR1), a VH-CDR2, and VH-CDR3 from SEQ ID NO: 1876 and a VL complementarity determining region 1 (VL-CDR1), a VL-CDR2, and a VL-CDR3 from SEQ ID NO: 1957, wherein said VL-CDR1, said VL-CDR2, said VL-CDR3, said VH-CDR1, said VH-CDR2, and said VH-CDR3 are defined according to Kabat, Chothia, IMGT, or AbM;

(ii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3342, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3478, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1337, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3614, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3750, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1473;

(iii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3403, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3539, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1398, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3675, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3811, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1534;

(iv) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2144, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2332, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 139, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2520, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2708, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 327,

(v) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3420, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3556, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1415, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3692, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3828, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1551; or

(vi) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3425, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3561, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1420, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3697, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3833, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1556.

4 . The method of claim 3 , wherein said antibody or said antigen binding fragment thereof comprises a VH-CDR1, a VH-CDR2, and VH-CDR3 from SEQ ID NO: 1876 and a VL-CDR1, a VL-CDR2, and a VL-CDR3 from SEQ ID NO: 1957, wherein said VH-CDR1, said VH-CDR2, said VH-CDR3, said VL-CDR1, said VL-CDR2, and said VL-CDR3 are defined according to Kabat, Chothia, IMGT, or AbM.

5 . The method of claim 4 , wherein said antibody or said antigen binding fragment thereof comprises a VL comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1957 and a VH comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1876.

6 . The method of claim 3 , wherein said antibody or said antigen binding fragment thereof comprises a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3342, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3478, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1337, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3614, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3750, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1473.

7 . The method of claim 6 , wherein said antibody or said antigen binding fragment thereof comprises a VL comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1745 and a VH comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1609.

8 . The method of claim 3 , wherein said antibody or said antigen binding fragment thereof comprises a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3403, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3539, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1398, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3675, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3811, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1534.

9 . The method of claim 8 , wherein said antibody or said antigen binding fragment thereof comprises a VL comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1806 and a VH comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1670.

10 . The method of claim 3 , wherein said antibody or said antigen binding fragment thereof comprises a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3420, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3556, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1415, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3692, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3828, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1551.

11 . The method of claim 10 , wherein said antibody or said antigen binding fragment thereof comprises a VL comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1823 and a VH comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1687.

12 . The method of claim 3 , wherein said antibody or said antigen binding fragment thereof comprises a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2144, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2332, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 139, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2520, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2708, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 327.

13 . The method of claim 12 , wherein said antibody or said antigen binding fragment thereof comprises a VL comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 703 and a VH comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 515.

14 . The method of claim 3 , wherein said antibody or said antigen binding fragment thereof comprises a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3425, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3561, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1420, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3697, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3833, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1556.

15 . The method of claim 14 , wherein said antibody or said antigen binding fragment thereof comprises a VL comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1828 and a VH comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1692.

16 . The method of claim 3 , wherein said antibody or said antigen binding fragment thereof binds to an erythropoietin receptor with a dissociation constant (Kd) of from 1×10 −12 M to 5×10 −7 M, wherein said Kd is measured by surface plasmon resonance, a biosensor system for measuring binding affinity, scintillation proximity assays, enzyme linked immunosorbent assay (ELISA), fluidic-free biolayer interferometry (BLI) assay, ORIGEN immunoassay (IGEN), fluorescence quenching, fluorescence transfer, yeast display, or any combination thereof.

17 . The method of claim 3 , wherein said cancer is resistant to immune checkpoint inhibitor therapy.

18 . The method of claim 3 , further comprising administering one or more immune checkpoint inhibitors to said patient.

19 . The method of claim 18 , wherein said one or more immune checkpoint inhibitors comprise a Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) inhibitor comprising an anti-CTLA-4 antibody, a Programmed Death I (PD-1) inhibitor comprising an anti-PD-1 antibody, or a Programmed Death Ligand 1 (PD-L1) inhibitor comprising an anti-PD-L1 antibody.

20 . The method of claim 18 , wherein said one or more immune checkpoint inhibitors comprise nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, durvalumab, ipilimumab, lirilumab, or BMS-986016.

21 . The method of claim 3 , wherein said antibody or said antigen binding fragment thereof is a bispecific antibody comprising a second antigen binding domain that binds to a signaling molecule associated with immune cells.

22 . The method of claim 21 , wherein said signaling molecule associated with immune cells is PD-L1, TIM3 or TREM2.

23 . The method of claim 3 , wherein said antibody or said antigen binding domain is a bispecific antibody comprising a second antigen binding domain that binds to an antigen associated with said cancer.

24 . The method of claim 3 , wherein the method treats said cancer.

25 . The method of claim 24 , wherein said cancer is selected from the group consisting of a lung cancer, a breast cancer, a colon cancer, a brain cancer, a skin cancer, a colorectal cancer, a liver cancer, and a lymph node metastasis.

26 . The method of claim 24 , wherein said cancer is selected from the group consisting of a melanoma, a hepatocarcinoma, and a liver metastasis.

27 . A method of treating cancer in a patient in need thereof, the method comprising administering to said patient an antibody or an antigen binding fragment thereof;

wherein said antibody or said antigen binding fragment thereof comprises:

(i) a VH complementarity determining region 1 (VH-CDR1), a VH-CDR2, and VH-CDR3 from SEQ ID NO: 1876 and a VL complementarity determining region 1 (VL-CDR1), a VL-CDR2, and a VL-CDR3 from SEQ ID NO: 1957, wherein said VL-CDR1, said VL-CDR2, said VL-CDR3, said VH-CDR1, said VH-CDR2, and said VH-CDR3 are defined according to Kabat, Chothia, IMGT, or AbM;

(ii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3342, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3478, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1337, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3614, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3750, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1473;

(iii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3403, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3539, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1398, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3675, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3811, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1534;

(iv) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2144, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2332, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 139, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2520, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2708, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 327,

(v) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3420, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3556, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1415, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3692, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3828, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1551; or

(vi) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3425, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3561, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1420, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3697, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3833, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1556.

28 . The method of claim 27 , wherein said antibody or said antigen binding fragment thereof comprises:

(i) a VH-CDR1, a VH-CDR2, and VH-CDR3 from SEQ ID NO: 1876 and a VL-CDR1, a VL-CDR2, and a VL-CDR3 from SEQ ID NO: 1957, wherein said VH-CDR1, said VH-CDR2, said VH-CDR3, said VL-CDR1, said VL-CDR2, and said VL-CDR3 are defined according to Kabat, Chothia, IMGT, or AbM, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1876 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1957;

(ii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3342, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3478, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1337, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3614, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3750, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1473, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1609 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1745;

(iii) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3403, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3539, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1398, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3675, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3811, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1534, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1670 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1806;

(iv) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2144, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2332, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 139, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2520, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 2708, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 327, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 515 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 703;

(v) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3420, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3556, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1415, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3692, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3828, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1551, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1687 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1823; or

(vi) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3425, a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3561, a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1420, a VL-CDR1 comprising an amino acid sequence set forth in SEQ ID NO: 3697, a VL-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3833, and a VL-CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 1556, and wherein the VH comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1692 and the VL comprises an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 1828.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: ENGLEMAN, EDGAR G.; ZHANG, XIANGYUE; CHIU, DAVID KUNG-CHUN
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 068517/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: YU, BO
To: IMMUNEDGE, INC.
Reel/Frame 068517/0857 →
Continuity (2)
Provisional Application 63317943 · Mar 8, 2022
Related Publication 20250129147A1 · Apr 24, 2025
References Cited (375)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4956778A · Naito · 1990 [cited by applicant]
US 5091513A · Huston et al. · 1992 [cited by applicant]
US 5132405A · Huston et al. · 1992 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5849500A · Breitling et al. · 1998 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6702705B1 · Von Borstel et al. · 2004 [cited by applicant]
US 7053050B2 · Yasuda · 2006 [cited by examiner]
US 7501121B2 · Tchistiakova et al. · 2009 [cited by applicant]
US 20030166871A1 · Barbas et al. · 2003 [cited by applicant]
US 20040009530A1 · Wilson et al. · 2004 [cited by applicant]
US 20050037421A1 · Honda et al. · 2005 [cited by applicant]
US 20070269379A1 · Mitragotri et al. · 2007 [cited by applicant]
US 20130150625A1 · Budzik et al. · 2013 [cited by applicant]
US 20230310539A1 · Kouji et al. · 2023 [cited by applicant]
EP 0125023A1 · 1984 [cited by applicant]
EP 0171496A2 · 1986 [cited by applicant]
EP 0173494A2 · 1986 [cited by applicant]
EP 0184187A2 · 1986 [cited by applicant]
EP 0388151A1 · 1990 [cited by applicant]
EP 0519596A1 · 1992 [cited by applicant]
WO WO8601533A1 · 1986 [cited by applicant]
WO WO8702671A1 · 1987 [cited by applicant]
WO WO9002809A1 · 1990 [cited by applicant]
WO WO9100906A1 · 1991 [cited by applicant]
WO WO9109967A1 · 1991 [cited by applicant]
WO WO9109968A1 · 1991 [cited by applicant]
WO WO9110741A1 · 1991 [cited by applicant]
WO WO9117271A1 · 1991 [cited by applicant]
WO WO9201047A1 · 1992 [cited by applicant]
WO WO9203917A1 · 1992 [cited by applicant]
WO WO9203918A1 · 1992 [cited by applicant]
WO WO9209690A2 · 1992 [cited by applicant]
WO WO9211383A1 · 1992 [cited by applicant]
WO WO9215679A1 · 1992 [cited by applicant]
WO WO9218619A1 · 1992 [cited by applicant]
WO WO9220791A1 · 1992 [cited by applicant]
WO WO9301288A1 · 1993 [cited by applicant]
WO WO9404678A1 · 1994 [cited by applicant]
WO WO9856915A2 · 1998 [cited by applicant]
WO WO9945110A1 · 1999 [cited by applicant]
WO WO9958572A1 · 1999 [cited by applicant]
WO WO0034784A1 · 2000 [cited by applicant]
WO WO0060070A1 · 2000 [cited by applicant]
WO WO0061637A1 · 2000 [cited by applicant]
WO WO0164942A1 · 2001 [cited by applicant]
WO WO2022025204A1 · 2022 [cited by applicant]
WO WO2023172990A2 · 2023 [cited by applicant]
Udupa KB (Dec. 14, 2006) World J Gastroenterol. 12(46):7460-7462 (doi: 10.3748/wjg.v12.i46.7460; http://www.wjgnet.com/1007-9327/12/7460.asp). [cited by examiner]
Paul, WE (1993) Fundamental Immunology, 3rd ed. Raven Press, NY, Chap. 9, pp. 292-295. [cited by examiner]
Rudikoff, S et al. (1982) Proc. Natl. Acad. Sci. USA, 79:1979-1983 (doi: 10.1073/pnas.79.6.1979). [cited by examiner]
Colman, PM (1994) Research in Immunology, Elsevier, NY, 145(1):33-36. [cited by examiner]
Bendig M. M. (1995) Methods: A Companion to Methods in Enzymology, 8:83-93. [cited by examiner]
MacCallum et al. (Oct. 11, 1996) J. Mol. Biol., 262(5):732-745. (doi: 10.1006/jmbi.1996.0548). [cited by examiner]
Casset et al.(2003) Biochemical and Biophysical Research Communications, 307:198-205. (doi: 10.1016/S0006-291X(03)01131-8). [cited by examiner]
Chen et al. (1995) EMBO J., 14(12):2784-2794. (doi: 10.1002/j.1460-2075.1995.tb07278.x). [cited by examiner]
Al-Lazikani, Bissan. et al. Standard Conformations for the Canonical Structures of Immunoglobulins. Journal of Molecular Biology 273(4):927-948 (1997). [cited by applicant]
Alnaeeli, M. et al. Erythropoietin and obesity-induced white adipose tissue inflammation: redefining the boundaries of the immunometabolism territory. Adipocyte 4(2):153-157 (2015). [cited by applicant]
Alnaeeli, M. et al. Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity. Diabetes 63(7):2415-2431 (2014). [cited by applicant]
Altschul, Stephen F. et al. Basic Local Alignment Search Tool. Journal of Molecular Biology 215(3):403-410 (1990). [cited by applicant]
Annese, T. et al. Erythropoietin in tumor angiogenesis. Experimental Cell Research 374(2):266-273 (2019). [cited by applicant]
Bajorath, J. et al. Conformational similarity and systematic displacement of complementarity determining region loops in high resolution antibody X-ray structures. Journal of Biological Chemistry 270(38):22081-22084 (19… [cited by applicant]
Barbas, Carlos F. et al. Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site. Proceedings of the National Academy of Sciences of the United States of America 88(18):7978-7982 (1991). [cited by applicant]
Basha, Genc. et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Molecular Therapy 19(12):2186-2200 (2011). [cited by applicant]
Better, Marc. et al. [cited by applicant]
Bhoopalan, Senthil Velan. et al. Erythropoietin regulation of red blood cell production: from bench to bedside and back. F1000Research 9:F1000-Faculty, 1-17 (2020). [cited by applicant]
Binz, H Kaspar. et al. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23(10):1257-1268 (2005). [cited by applicant]
Bird, Robert E. et al. Single-chain Antigen-binding Proteins. Science 242(4877):423-426 (1988). [cited by applicant]
Boerner, Paula. et al. Production Of Antigen-Specific Human Monoclonal Antibodies From In Vitro-primed Human Splenocytes. Journal of Immunology 147(1):86-95 (1991). [cited by applicant]
Bonifaz, Laura. et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral … [cited by applicant]
Brines, M. et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proceedings of the National Academy of Sciences 101(41):14907-14912 (2004). [cited by applicant]
Brines, Michael, and Anthony Cerami. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6:484-494 (2005). [cited by applicant]
Broxmeyer, H. E. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. The Journal of Experimental Medicine 210(2):205-208 (2013). [cited by applicant]
Bruggemann, Marianne. et al. Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals. The Year in immunology 7:33-40 (1993). [cited by applicant]
Bruggemann, Marianne. et al. Human antibody production in transgenic mice: expression from 100kb of the human IgH locus. European Journal of Immunology 21(5):1323-1326 (1991). [cited by applicant]
Cantarelli, Chiara. et al. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am J Transplant 19(9):2407-2414 (2019). [cited by applicant]
Carter, Paul. et al. Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy. PNAS USA 89(10):4285-4289 (1992). [cited by applicant]
Chothia, Cyrus, and Arthur M. Lesk. Canonical Structures for the Hypervariable Regions of Immunoglobulins. Journal of Molecular Biology 196(4):901-917 (1987). [cited by applicant]
Chothia, Cyrus. et al. Conformations of Immunoglobulin Hypervariable Regions. Nature 342(6252):877-883 (1989). [cited by applicant]
Chothia, Cyrus. et al. Structural Repertoire of the Human VH Segments. Journal of Molecular Biology 227(3):799-817 (1992). [cited by applicant]
Cifuentes-Rius, Anna. et al. Inducing immune tolerance with dendritic cell-targeting nanomedicines. Nat Nanotechnol 16(1):37-46 (2021). [cited by applicant]
Clackson, Tim. et al. Making Antibody Fragments using Phage Display Libraries. Nature 352(6336):624-628 (1991). [cited by applicant]
ClinicalTrials.gov Identifier: NCT01004822. A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors, Record created Oct. 28, 2009. pp. 1-17. [retrieved on Jul. 12, 2024] Ava… [cited by applicant]
Co, M S. et al. Humanized antibodies for antiviral therapy. Proc. Natl.Acad. Sci. USA 88(7):2869-2873 (1992). [cited by applicant]
Co, M.S. et al., Chimeric and Humanized antibodies with specificity for the CD33 antigen. The Journal Immunology 148(4):1149-1154 (1992). [cited by applicant]
Colcher, David. et al. Single-Chain Antibodies in Pancreatic Cancer. Annals of the New York Academy of Sciences 880:263-280 (1999). [cited by applicant]
Cole, S.P.C. et al. The EBV-Hybridoma Technique and its Application to Human Lung Cancer. Monoclonal Antibodies and Cancer Therapy 27:77-96 (1985). [cited by applicant]
Feng, D F, and R F Doolittle. Progressive Sequence Alignment as a Prerequisite to Correct Phylogenetic Trees. Journal of Molecular Evolution 25(4):351-360 (1987). [cited by applicant]
Fuchs, Patrick. et al. Targeting recombinant antibodies to the surface of [cited by applicant]
Garrard, Lisa. et al. FAB Assembly And Enrichment In A Monovalent Phage Display System. Biotechnology 9(12):1373-1377 (1991). [cited by applicant]
Gram, Hermann. et al. In Vitro Selection and Affinity Maturation of Antibodies From a Naive Combinatorial Immunoglobulin Library. Proceedings of the National Academy of Sciences of the United States of America 89(8):357… [cited by applicant]
Green, L.L. et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACS. Nature Genet 7:13-21 (1994). [cited by applicant]
Griffiths, Andrew D. et al. Human anti-self antibodies with high specificity from phage display libraries. The EMBO Journal 12(2):725-734 (1993). [cited by applicant]
Hawkins, Robert E. et al. Selection of Phage Antibodies By Binding Affinity Mimicking Affinity Matruation. Journal of Molecular Biology 226(3):889-896 (1992). [cited by applicant]
Hay, Beverly N. et al. Bacteriophage Cloning and [cited by applicant]
Henikoff, Seteven, and J G Henikoff. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 89(22):10915-10919 (1992). [cited by applicant]
Hey, Thomas. et al. Artificial, Non-Antibody Binding Proteins For Pharmaceutical And Industrial Applications. Trends in Biotechnology. 23(10):514-522 (2005). [cited by applicant]
Heyes, James. et al. Cationic Lipid Saturation Influences Intracellular Delivery of Encapsulated Nucleic Acids. Journal of Controlled Release 107(2):276-287 (2005). [cited by applicant]
Higgins, Desmond G, and Paul M. Sharp. Fast and Sensitive Multiple Sequence Alignments on a Microcomputer. Bioinformatics 5(2):151-153 (1989). [cited by applicant]
Hoogenboom, Hennie R, and Greg Winter. By-Passing Immunisation: Human Antibodies From Synthetic Repertoires Of Germline VH Gene Segments Rearranged In Vitro. Journal of Molecular Biology 227(2):381-388 (1992). [cited by applicant]
Hoogenboom, Hennie R. et al. Multi-Subunit Proteins on the Surface of Filamentous Phage: Methodologies for Displaying Antibody (Fab) Heavy and Light Chains. Nucleic Acids Research 19(15):4133-4137 (1991). [cited by applicant]
Hou, Xucheng. et al. Lipid Nanoparticles for mRNA Delivery. Nature Reviews Materials 6:1078-1094 (2021). [cited by applicant]
Huse, William D. et al. Generation Of A Large Combinatorial Library Of The Immunoglobulin Repertoire In Phage Lambda. Science 246(4935):1275-1281 (1989). [cited by applicant]
Huston, James S. et al. Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in [cited by applicant]
Jang, Hochung. et al. Nanoparticles targeting innate immune cells in tumor microenvironment. International journal of molecular sciences 22(18):10009, 1-20 (2021). [cited by applicant]
Jayaraman, Muthusamy et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 51(34):8529-8533 (2012). [cited by applicant]
Jones, Peter T. et al. Replacing The Complementarity-determining Regions In A Human Antibody With Those From A Mouse. Nature 321(6069):522-525 (1986). [cited by applicant]
Kabat, Elvin A. et al. Sequences of Proteins of Immunological Interest, 5th Edition. U.S. Department of Health and Human Services NIH Publication No. 91-3242 (1991). [cited by applicant]
Karlin, Samuel. et al. Applications and Statistics for Multiple High-scoring Segments in Molecular Sequences. PNAS USA 90(12):5873-5877 (1993). [cited by applicant]
Kostelny, S A. et al. Formation of a Bispecific Antibody by the Use of Leucine Zippers. Journal of Immunology 148(5):1547-1553 (1992). [cited by applicant]
Lee et al.: β Common Receptor Mediates Erythropoietin-Conferred Protection on OxLDL-Induced Lipid Accumulation and Inflammation in Macrophages. Mediators Inflamm 2015: 439759; pp. 1-13 (2015). [cited by applicant]
Lefranc, Marie-Paule. IMGT, the international ImMunoGeneTics database. Nucleic Acids Research 29(1):207-209 (2001). [cited by applicant]
Liu, Alvin. et al. Chimeric Mouse-human IgG1 Antibody that can Mediate Lysis of Cancer Cells. Proceedings of the National Academy of Sciences of the United States of America 84(10):3439-3443 (1987). [cited by applicant]
Liu, Alvin Y. et al. Production of a Mouse-human Chimeric Monoclonal Antibody to CD20 With Potent Fc-dependent Biologic Activity. Journal of Immunology 139(10):3521-3526 (1987). [cited by applicant]
Lonberg, Nils. et al. Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications. Nature 368(6474):856-859 (1994). [cited by applicant]
Luo, B. et al. Erythropoeitin signaling in macrophages promotes dying cell clearance and immune tolerance. Immunity Article 44(2):287-302 (2016). [cited by applicant]
Maccallum, Robert M. et al. Antibody-Antigen Interactions: Contact Analysis And Binding Site Topography. Journal of Molecular Biology 262(5):732-745 (1996). [cited by applicant]
Maier, Martin A. et al. Biodegradable lipids enabling rapidly eliminating lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther 21(8):1570-1578 (2013). [cited by applicant]
Marks, J D. et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 222(3):581-597 (1991). [cited by applicant]
Marks, James. et al. By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling. Bio/Technology 10(7):779-783 (1992). [cited by applicant]
Martin, A C. et al. Modeling antibody hypervariable loops: a combined algorithm. PNAS USA 86(23):9268-9272 (1989). [cited by applicant]
Martin, A. C. et al. Molecular modeling of antibody combining sites. Methods Enzymol 203:121-153 (1991). [cited by applicant]
Martin, Franck. et al. The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6. The EMBO Journal 13(22):5303-5309 (1994). [cited by applicant]
McConnell, Stephen J. et al. Tendamistat as a Scaffold for Conformationally Constrained Phage Peptide Libraries. Journal of Molecular Biology 250(4):460-470 (1995). [cited by applicant]
Milletti, Francesca. et al. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discovery Today 17(15-16):850-860 (2012). [cited by applicant]
Morrison, Sherie L et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Pnas USA 81(21):6851-6855 (1984). [cited by applicant]
Muyldermans, Serge et al. Sequence And Structure Of Vh Domain From Naturally Occurring Camel Heavy Chain Immunoglobulins Lacking Light Chains. Protein Engineering 7(9): 1129-1135 (1994). [cited by applicant]
Nairz, M et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kb-inducible immune pathways. Immunity Article 34(1):61-74 (2011). [cited by applicant]
Needleman, Saul B, and Christian D. Wunsch. A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins. Journal of Molecular Biology 48(3):443- 453 (1970). [cited by applicant]
Nishimura, Yushi et al. Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen. Cancer Research 47(4):999-1005 (1987). [cited by applicant]
PCT/US2023/063997 International Preliminary Report on Patentability dated Sep. 19, 2024. [cited by applicant]
PCT/US2023/063997 International Search Report and Written Opinion dated Sep. 20, 2023. [cited by applicant]
Pearson, William R, and David J. Lipman. Improved Tools for Biological Sequence Comparison. Proceedings of the National Academy of Sciences 85(8):2444-2448 (1988). [cited by applicant]
Pedersen, Jan et al. Antibody modeling: beyond homology. Immunomethods 1(2):126-136 (1992). [cited by applicant]
Peng, Bo. et al. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell death and disease 11(2):79, 1-12 (2020). [cited by applicant]
Prausnitz, Mark R. et al. Transdermal drug delivery. Nature Biotechnology 26(11):1261-1268 (2008). [cited by applicant]
Rader, C. et al. A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries. PNAS USA 95(15):8910-8915 (1998). [cited by applicant]
Rader, C. et al. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. Journal of Biological Chemistry 275(18):13668-13676 (2000). [cited by applicant]
Reiter, Yoram. et al. Antibody Engineering of Recombinant Fv Immunotoxins for Improved Targeting of Cancer: Disulfide-stabilized Fv Immunotoxins. Clin Cancer Res 2(2):245-252 (1996). [cited by applicant]
Rohaan, Maartje W. et al. Adoptive cellular therapies: the current landscape. Virchows Archiv 474(4):449-461 (2019). Published Online Nov. 23, 2018. [cited by applicant]
Routledge, E.G. et al. A humanized monovalent CD3 antibody which can activate homologous complement. Eur. J. Immunol. 21(11):2717-2725 (1991). [cited by applicant]
Ruan, Renquan. et al. Recent advances in peptides for enhancing transdermal macromolecular drug delivery. Therapeutic Delivery 7(2):89-100 (2016). [cited by applicant]
Ruiz, Manuel. et al. IMGT, the international ImMunoGeneTics database. Nucleic acids research 28(1):219-221 (2000). [cited by applicant]
Semenza, Gregg L. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood, The Journal of the American Society of Hematology 114(10):2015-2019 (2009). [cited by applicant]
Semple, Sean C. et al. Rational design of cationic lipids for siRNA delivery. Nature biotechnology 28(2):172-176 (2010). [cited by applicant]
Shaw, Denise R. et al. Mouse/Human Chimeric Antibodies to a Tumor-Associated Antigen: Biologic Activity of the Four Human IgG Subclasses. Journal of the National Cancer Institute 80(19):1553-1559 (1988). [cited by applicant]
Sheets, Michael D. et al. Efficient Construction Of A Large Nonimmune Phage Antibody Library: The Production Of High-affinity Human Single-chain Antibodies To Protein Antigens. Proceedings of the National Academy of Sci… [cited by applicant]
Smith, Temple F, and Michael S. Waterman. Comparison of Biosequences. Advances in Applied Mathematics 2(4):482-489 (1981). [cited by applicant]
Songsivilai, S et al. Bispecific antibody: a tool for diagnosis and treatment of disease. Clinical and Experimental Immunology vol. 79(3):315-321 (1990). [cited by applicant]
Spiess, Christoph. et al. Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies. Molecular Immunology 67(2):95-106 (2015). [cited by applicant]
Steinberger, P. et al. Generation and characterization of a recombinant human ccr5-specific antibody. Protein Structure and Folding 275(46):36073-36078 (2000). [cited by applicant]
Su, Kuo-Hui. et al. Beta Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. Journal of cellular physiology 226(12):3330-3339 (2011). [cited by applicant]
Sun, Lee K. et al. Chimeric Antibody With Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A. Proceedings of the National Academy of Sciences of the United States of Am… [cited by applicant]
Suresh, Sukanya. et al. The many facets of erythropoietin physiologic and metabolic response. Frontiers in physiology 10:1534, 1-20 (2020). [cited by applicant]
Teng, R. et al. Acute erythropoietin cardioprotection is mediated by endothelial response. Basic Research in Cardiology 106(3):343-354 (2011). [cited by applicant]
Thompson, J D. et al. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Research 22(22):4… [cited by applicant]
Tramontano, Anna et al. Framework Residue 71 Is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the VH Domains of Immunoglobulins. Journal of Molecular Biology 215(1):175-182 (… [cited by applicant]
Tramontano, Anna. et al. The Making of the Minibody: an Engineered Beta-Protein for the Display of Conformationally Constrained Peptides. Journal of Molecular Recognition 7(1):9-24 (1994). [cited by applicant]
Tuaillon, Nadine et al. Human Immunoglobulin Heavy-Chain Minilocus Recombination in Transgenic Mice: Gene-Segment Use in Mu and Gamma Transcripts. Proceedings of the National Academy of Sciences of the United States of … [cited by applicant]
Vaughan, Tristan. et al. Human Antibodies With Sub-Nanomolar Affinities Isolated From A Large Non-immunized Phage Display Library. Nature Biotechnology 14(3):309-314 (1996). [cited by applicant]
Wang, L. et al. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35(7):1732-1737 (2004). [cited by applicant]
Wei et al.: Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170:1120-1133 (2017). [cited by applicant]
Whittle, N. et al. Expression in COS cells of a mouse-human chimaeric B72.3 Antibody. Protein Engineering 1(6):499-505 (1987). [cited by applicant]
Wood, Clive R. et al. The Synthesis and in Vivo Assembly of Functional Antibodies in Yeast. Nature 314(6010):446-449 (1985). [cited by applicant]
Abramson, J. et al. The emerging family of RORγt+ antigen-presenting cells. Nature Reviews Immunology 24(1):64-77 (2024). [cited by applicant]
Aizarani, Nadim. et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature 572(7768):199-204 (2019). [cited by applicant]
Akagbosu, Blossom. et al. Novel antigen-presenting cell imparts Treg-dependent tolerance to gut microbiota. Nature 610(7933):752-760 (2022). [cited by applicant]
Alaluf, Emmanuelle. et al. Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages. JCI Insight 5(11):e133929, 1-16 (2020). [cited by applicant]
Anders, Simon. et al. HTSeq—a Python Framework to Work With High-throughput Sequencing Data. Bioinformatics 31(2):166-169 (2015). Published Online Sep. 25, 2014. [cited by applicant]
Anderson III, David A. et al. Genetic Models of Human and Mouse Dendritic Cell Development and Function. Nature Reviews Immunology 21(2):101-115 (2021). [cited by applicant]
Anderson III, David A. et al. Models of dendritic cell development correlate ontogeny with function. Advances in Immunology 143:99-119 (2019). [cited by applicant]
Arcasoy, Murat O. et al. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Modern Pathology 18(3):421-430 (2005). [cited by applicant]
Ardouin, Laurence. et al. Broad and largely concordant molecular changes characterize tolerogenic and immunogenic dendritic cell maturation in thymus and periphery. Immunity 45(2):305-318 (2016). [cited by applicant]
Ayala, Mariela A. Moreno. et al. CXCR3 Expression in Regulatory T Cells Drives Interactions With Type I Dendritic Cells in Tumors to Restrict CD8+ T Cell Antitumor Immunity. Immunity 56(7):1613-1630 (2023). [cited by applicant]
Azukizawa, Hiroaki. et al. Steady State Migratory RelB+ Langerin+ Dermal Dendritic Cells Mediate Peripheral Induction of Antigen-specific Cd4+ Cd25+ Foxp3+ Regulatory T Cells. European Journal of Immunology 41(5):1420-1… [cited by applicant]
Badoual et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 73(1):128-138 (2013). [cited by applicant]
Balan, Sreekumar. et al. Unexplored horizons of cDC1 in immunity and tolerance. Advances in Immunology 148:49-91 (2020). [cited by applicant]
Beattie, Lynette. et al. Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions. Journal of hepatology 65(4):758-768 (2016). [cited by applicant]
Bezzi, Marco. et al. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nature medicine 24(2):165-175 (2018). [cited by applicant]
Billingham, R. E. et al. Actively acquired tolerance of foreign cells. Nature 172(4379):603-606 (1953). [cited by applicant]
Bin, Sofia. et al. Endogenous Erythropoietin Has Immunoregulatory Functions That Limit the Expression of Autoimmune Kidney Disease in Mice. Frontiers in Immunology 14:1195662, 1-9 (2023). [cited by applicant]
Binnewies, Mikhail. et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell 177(3):556-571 (2019). [cited by applicant]
Blagosklonny, Mikhail V. et al. p53 inhibits hypoxia-inducible factor-stimulated transcription. Journal of Biological Chemistry 273(20):11995-11998 (1998). [cited by applicant]
Blanco, Tomas. et al. Conventional type I migratory CD103+ dendritic cells are required for corneal allograft survival. Mucosal immunology 16(5):711-726 (2023). [cited by applicant]
Bluestone, Jeffrey A. et al. Tolerance in the age of immunotherapy. The New England Journal of Medicine 383(12):1156-1166 (2020). [cited by applicant]
Bod, Lloyd. et al. B-cell-specific Checkpoint Molecules That Regulate Anti-tumour Immunity. Nature 619(7969):348-356 (2023). [cited by applicant]
Bolger, Anthony M. et al. Trimmomatic: A Flexible Trimmer For Illumina Sequence Data. Bioinformatics 30(15):2114-2120 (2014). [cited by applicant]
Bonaventura et al., Cold tumors: a therapeutic challenge for immunotherapy. Frontiers in Immunology 10:168 (2019). [cited by applicant]
Bories, Gael F. P. et al. Macrophage metabolic adaptation to heme detoxification involves CO-dependent activation of the pentose phosphate pathway. Blood 136(13):1535-1548 (2020). [cited by applicant]
Borst, Jannie. et al. CD4+ T Cell Help in Cancer Immunology and Immunotherapy. Nature Reviews Immunology 18(10):635-647 (2018). [cited by applicant]
Bosteels, Victor, and Sophie Janssens. Striking a Balance: New Perspectives on Homeostatic Dendritic Cell Maturation. Nature Reviews Immunology 25(2):125-140 (2025). Published Online Sep. 17, 2024. [cited by applicant]
Bosteels, Victor. et al. LXR signaling controls homeostatic dendritic cell maturation. Science Immunology 8(83):eadd3955 (2023). [cited by applicant]
Bottcher, Jan P., and Caetano Reis e Sousa. The role of type 1 conventional dendritic cells in cancer immunity. Trends in Cancer 4(11):784-792 (2018). [cited by applicant]
Bourque, Jessica. et al. Immunomodulatory bonds of the partnership between dendritic cells and T cells. Critical reviews in immunology 38(5):379-401 (2018). [cited by applicant]
Brown, Hailey. et al. Lymph Node Sharing Between Pancreas, Gut, and Liver Leads to Immune Crosstalk and Regulation of Pancreatic Autoimmunity. Immunity 56(9):2070-2085 (2023). [cited by applicant]
Broz, Miranda L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer cell 26(5):638-652 (2014). [cited by applicant]
Campos Canesso, Maria Cecilia. et al. Identification of antigen-presenting cell-T cell interactions driving immune responses to food. Science 387(6739):eado5088, 1-28 (2025). [cited by applicant]
Casanova-Acebes, Maria. et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature 595(7868):578-584 (2021). [cited by applicant]
Cheng, Sijin. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184(3):792-809 (2021). [cited by applicant]
Chiu, David Kung-Chun. et al. Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice. Gastroenterol… [cited by applicant]
Chow, Andrew. et al. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. Cancer Cell 39(7):973-988.e9 (2021). [cited by applicant]
Consonni, Francesca Maria. et al. Heme catabolismby tumor-associated macrophages controls metastasis formation. Nature immunology 22(5): 595-606 (2021). [cited by applicant]
Crozat, Karine, et al., The XC Chemokine Receptor 1 is a Conserved Selective Marker of Mammalian Cells Homologous to Mouse CD8a+ Dendritic Cells. Journal of Experimental Medicine 207(6):1283-1292 (2010). [cited by applicant]
Cruz De Casas, Paulina. et al. Same Yet Different—how Lymph Node Heterogeneity Affects Immune Responses. Nature Reviews Immunology 24(5):358-374 (2024). [cited by applicant]
De Simone, Giorgia. et al. Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming. Immunity 54(9):2089-2100.e8 (2021). [cited by applicant]
Debeljak, Natasa. et al. Erythropoietin and Cancer: the Unintended Consequences of Anemia Correction. Frontiers in Immunology 5:563, 1-15 (2014). [cited by applicant]
Devey, Luke. et al. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. Molecular Therapy 17(1):65-72 (2009). [cited by applicant]
Dikiy, Stanislav, and Alexander Y Rudensky. Principles of regulatory T cell function. Immunity 56(2):240-255 (2023). [cited by applicant]
Dinkova-Kostova, Albena T., and Ian M. Copple. Advances and challenges in therapeutic targeting of NRF2. Trends in pharmacological sciences 44(3):137-149 (2023). [cited by applicant]
Dixon, Karen O. et al. TIM-3 Restrains Anti-tumour Immunity by Regulating Inflammasome Activation. Nature 595(7865):101-106 (2021). [cited by applicant]
Dobin, Alexander. et al. STAR: Ultrafast Universal RNA-seq Aligner. Bioinformatics 29(1):15-21 (2013). [cited by applicant]
Doran, Amanda C. et al. Efferocytosis in health and disease. Nature reviews. Immunology 20(4):254-267 (2020). Published online Dec. 10, 2019. [cited by applicant]
Dudziak, Diana. et al. Differential Antigen Processing by Dendritic Cell Subsets in Vivo. Science 315(5808):107-111 (2007). [cited by applicant]
Enders, Marika. et al. Splenic red pulp macrophages cross-prime early effector CTL that provide rapid defense against viral infections. The Journal of Immunology 204(1):87-100 (2020). Published Online Nov. 27, 2019. [cited by applicant]
Eswarappa, Meghana. et al. Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone. Frontiers in Immunology 12:639370, 1-9 (2021). [cited by applicant]
Farha, Mark. et al. Characterization of the tumor immune microenvironment identifies M0 macrophage-enriched cluster as a poor prognostic factor in hepatocellular carcinoma. JCO Clinical Cancer Informatics 4:1002-1013 (2… [cited by applicant]
Ferris, Stephen T. et al. cDC1 Prime and are Licensed by CD4+ T Cells to Induce Anti-tumour Immunity. Nature 584(7822):624-629 (2020). [cited by applicant]
Forster, Reinhold. et al. CCR7 and its Ligands: Balancing Immunity and Tolerance. Nature Reviews Immunology 8(5):362-371 (2008). [cited by applicant]
Fu, Liuhui. et al. RORγt-dependent antigen-presenting cells direct regulatory T cell-mediated tolerance to food antigen. Biorxiv :1-43 (2024). [cited by applicant]
Gajewski, Thomas F. The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. Seminars in Oncology 42(4):663-671 (2015). [cited by applicant]
Galon et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964 (2006). [cited by applicant]
Galon, Jerome, and Daniela Bruni. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature reviews Drug discovery 18(3):197-218 (2019). [cited by applicant]
Gargaro, Marco. et al. Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. Immunity 55(6):1032-1050 (2022). [cited by applicant]
Ge, Yun. et al. Efferocytosis and its role in inflammatory disorders. Frontiers in cell and developmental biology 10:839248, 1-15 (2022). [cited by applicant]
Genc, Kursad. et al. Erythropoietin induces nuclear translocation of Nrf2 and heme oxygenase-1 expression in SH-SY5Y cells. Cell Biochemistry and Function: Cellular biochemistry and its modulation by active agents or di… [cited by applicant]
Gonzales, Gerone A. et al. The pore-forming Apolipoprotein APOL7C Drives Phagosomal Rupture and Antigen Cross-presentation by Dendritic Cells. Science Immunology 9(101):eadn2168, 1-20 (2024). [cited by applicant]
Gozzelino, Raffaella. et al. Mechanisms of cell protection by heme oxygenase-1. Annual review of pharmacology and toxicology 50(1):323-354 (2010). [cited by applicant]
Grewal et al.: The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 153:85-106 (1996). [cited by applicant]
Gu, Zuguang. et al. Complex Heatmap Visualization. iMeta 1(3):e43, 1-15 (2022). [cited by applicant]
Han, Yanmei. et al. Tumor-induced generation of splenic erythroblast-like Ter-cells promotes tumor progression. Cell 173(3):634-648.e12 (2018). [cited by applicant]
Hanayama, Rikinari. et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304(5674):1147-1150 (2004). [cited by applicant]
Hao, Yuhan. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nature biotechnology 42(2):293-304 (2024). [cited by applicant]
Hashimoto, Kahoko. et al. A conditional null allele of the major histocompatibility IA-beta chain gene. Genesis 32(2):152-153 (2002). [cited by applicant]
Hastir, Jean-Francois. et al. Hepatocarcinoma induces a tumor necrosis factor-dependent Kupffer cell death pathway that favors its proliferation upon partial hepatectomy. Frontiers in Oncology 10:547013, 1-13 (2020). [cited by applicant]
Heinrich, Achim C. et al. A mouse model for visualization and conditional mutations in the erythroid lineage. Blood 104(3):659-666 (2004). [cited by applicant]
Heymann, Felix. et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 62(1):279-291 (2015). [cited by applicant]
Hildner et al., Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322:1097-1100 (2008). [cited by applicant]
Hirano, Ryuichiro. et al. Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases. Communications Biology 6(1):144, 1-11 (2023). [cited by applicant]
Hongo, David. et al. Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood 129(12):1718-1728 (2017). [cited by applicant]
Huang, Qizhao. et al. The Primordial Differentiation of Tumor-specific Memory CD8+ T Cells as Bona Fide Responders to PD-1/PD-L1 Blockade in Draining Lymph Nodes. Cell 185(22):4049-4066 (2022). [cited by applicant]
Huang, Xiangang. et al. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages. Nature Protocols 17(3):748-780 (2022). [cited by applicant]
Iberg, Courtney A. et al. Dendritic Cells as Inducers of Peripheral Tolerance. Trends in Immunology 38(11):793-804 (2017). [cited by applicant]
Iberg, Courtney A. et al. TNF-α sculpts a maturation process in vivo by pruning tolerogenic dendritic cells. Cell Reports 39(2):110657, 1-39 (2022). [cited by applicant]
Idoyaga, Juliana. et al. Specialized role of migratory dendritic cells in peripheral tolerance induction. The Journal of clinical investigation 123(2):844-854 (2013). [cited by applicant]
Iyoda, Tomonori. et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. The Journal of experimental medicine 195(10):1289-1302 (2002). [cited by applicant]
Jansen, Caroline S. et al. An Intra-tumoral Niche Maintains and Differentiates Stem-like CD8 T Cells. Nature 576(7787):465-470 (2019). [cited by applicant]
Jung, Keunok. et al. Protective role of V-set and immunoglobulin domain-containing 4 expressed on kupffer cells during immune-mediated liver injury by inducing tolerance of liver T-and natural killer T-cells. Hepatology… [cited by applicant]
Kapitsinou, Pinelopi P. et al. Hepatic HIF-2 Regulates Erythropoietic Responses to Hypoxia in Renal Anemia. Blood, The Journal of the American Society of Hematology 116(16):3039-3048 (2010). [cited by applicant]
Kedmi, Ranit. et al. A RORγt+ cell instructs gut microbiota-specific Treg cell differentiation. Nature 610(7933):737-743 (2022). [cited by applicant]
Kidani, Yujiro. et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proceedings of the National Academy of Sciences 119(7):e211… [cited by applicant]
Kim, Daehwan. et al. Graph-based Genome Alignment and Genotyping with HISAT2 and HISAT-genotype. Nature Biotechnology 37(8):907-915 (2019). [cited by applicant]
Kim, Jeong M. et al. Regulatory T Cells Prevent Catastrophic Autoimmunity Throughout the Lifespan of Mice. Nature Immunology 8(2):191-197 (2007). [cited by applicant]
Kinder, Jeremy. M. et al. Cross-generational reproductive fitness enforced by microchimeric maternal cells. Cell 162(3):505-515 (2015). [cited by applicant]
Kobayashi, Eri H. et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nature Communications 7(1):11624, 1-14 (2016). [cited by applicant]
Kuhrt, David, and Don M Wojchowski. Emerging EPO and EPO receptor regulators and signal transducers. Blood 125(23):3536-3541 (2015). [cited by applicant]
Kurtulus, Sema. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1-CD8+ tumor-infiltrating T cells. Immunity 50(1):181-194 (2019). [cited by applicant]
Langmead, Ben et al. Fast gapped-read alignment with Bowtie 2. Nature methods 9(4):357-359 (2012). [cited by applicant]
Lax, Brianna M. et al. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Proceedings of the National Academy of Sciences 120(31):e2300895120… [cited by applicant]
Lehmann, Christian HK. et al. DC Subset-specific Induction of T Cell Responses Upon Antigen Uptake via Fc gamma Receptors in Vivo. Journal of Experimental Medicine 214(5):1509-1528 (2017). [cited by applicant]
Lei, Xin. et al. CD4+ Helper T Cells Endow cDC1 With Cancer-impeding Functions in the Human Tumor Micro-environment. Nature Communications 14(1):217, 1-14 (2023). [cited by applicant]
Li, Jiawei. et al. CHBP Induces Stronger Immunosuppressive CD127+ M-MDSC Via Erythropoietin Receptor. Cell Death and Disease 12(2):177, 1-12 (2021). [cited by applicant]
Li, Weiyang et al. Heterogeneity and function of kupffer cells in liver injury. Frontiers in Immunology 13:940867, 1-13 (2022). [cited by applicant]
Liberzon, Arthur et al. The molecular signatures database hallmark gene set collection. Cell systems 1(6):417-425 (2015). [cited by applicant]
Lisowska, Katarzyna A. et al. Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment. Artificial Organs 34(8):654-… [cited by applicant]
Liu, Fu-Tong, and Sean R. Stowell. The Role of Galectins in Immunity and Infection. Nature Reviews Immunology 23(8):479-494 (2023). [cited by applicant]
Liu, Kang. et al. Immune tolerance after delivery of dying cells to dendritic cells in situ. The Journal of experimental medicine196(8):1091-1097 (2002). [cited by applicant]
Liu, Zhaoyuan. et al. Fate mapping via Ms4a3-expression history traces monocyte-derived cells. Cell 178(6):1509-1525 (2019). [cited by applicant]
Long, Haixia. et al. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. Cancer cell 40(6):674-693.e7 (2022). [cited by applicant]
Love, Michael I. et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15(12):550, 1-21 (2014). [cited by applicant]
Lyu, Mengze. et al. ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut. Nature 610(7933):744-751 (2022). [cited by applicant]
Macparland, Sonya A. et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nature Communications 9(1):4383, 1-21 (2018). [cited by applicant]
Magen, Assaf. et al. Intratumoral Dendritic Cell-CD4+ T Helper Cell Niches Enable CD8+ T Cell Differentiation Following PD-1 Blockade in Hepatocellular Carcinoma. Nature Medicine 29(6):1389-1399 (2023). [cited by applicant]
Maier, Barbara. et al. A Conserved Dendritic-cell Regulatory Program Limits Antitumour Immunity. Nature 580(7802):257-262 (2020). [cited by applicant]
Mair, Florian. et al. Extricating Human Tumour Immune Alterations From Tissue Inflammation. Nature 605(7911):728-735 (2022). [cited by applicant]
McEachern, Elisa. et al. Erythropoietin Administration Expands Regulatory T Cells in Patients With Autoimmune Hepatitis. Journal of Autoimmunity 119:102629, 1-7 (2021). [cited by applicant]
Mcginnis et al. MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. Nat Methods. Jul. 2019; 16(7):619-626. doi: 10.1038/s41592-019-0433-8. Epub Jun. 17, 2019. [cited by applicant]
Mcgrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Annals of Oncology 32(5):661-672 (2021). [cited by applicant]
Mehrotra, Parul, and Kodi S. Ravichandran. Drugging the Efferocytosis Process: Concepts and Opportunities. Nature Reviews Drug Discovery 21(8):601-620 (2022). [cited by applicant]
Meiser, Philippa. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41(8):1498-1515.e10 (2023). [cited by applicant]
Mellman, Ira. et al. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity 56(10):2188-2205 (2023). [cited by applicant]
Meredith et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med 209:1153-1165 (2012). [cited by applicant]
Miller et al., Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 20(3):326-336 (2019). [cited by applicant]
Minutti, Carlos M. et al. Distinct ontogenetic lineages dictate cDC2 heterogeneity. Nature Immunology 25(3):448-461 (2024). [cited by applicant]
Moon, James J. et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire Diversity and response magnitude. Immunity 27(2):203-213 (2007). [cited by applicant]
Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genetics 34(3):267-273 (2003). [cited by applicant]
Murphy, Kenneth M. Transcriptional control of dendritic cell development. Advances in immunology 120:239-267 (2013). [cited by applicant]
Murphy, Theresa L., and Kenneth M. Murphy. Dendritic cells in cancer immunology. Cellular and molecular immunology 19(1):3-13 (2022). Published Online Sep. 3, 2021. [cited by applicant]
Narasimhan, Hamsa. et al. Cross-species analyses reveal RORγt-expressing dendritic cells are a lineage of antigen presenting cells conserved across tissues. Biorxiv :1-65 (2024). [cited by applicant]
Newman, Aaron M et al. Robust Enumeration of Cell Subsets From Tissue Expression Profiles. Nature Methods vol. 12,5: pp. 453-457 (2015). [cited by applicant]
Noelia, A-Gonzalez. et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31(2):245-258 (2009). [cited by applicant]
Ohara, Ray A. et al. The evolving biology of cross-presentation. Seminars in immunology 66:101711, 1-49 (2023). [cited by applicant]
Ohl, Lars. et al. CCR7 Governs Skin Dendritic Cell Migration Under Inflammatory and Steady-state Conditions. Immunity 21(2):279-288 (2004). [cited by applicant]
Parisotto, Yollanda F. et al. Thetis cells induce food-specific Treg cell differentiation and oral tolerance. Biorxiv :1-29 (2024). [cited by applicant]
Phipson, Belinda. et al. Propeller: testing for differences in cell type proportions in single cell data. Bioinformatics 38(20):4720-4726 (2022). [cited by applicant]
Pittet, Mikael J. et al. Dendritic Cells as Shepherds of T Cell Immunity in Cancer. Immunity 56(10):2218-2230 (2023). [cited by applicant]
Prokhnevska, Nataliya. et al. CD8+ T Cell Activation in Cancer Comprises an Initial Activation Phase in Lymph Nodes Followed by Effector Differentiation Within the Tumor. Immunity 56(1):107-124 (2023). [cited by applicant]
Puttock, E. H. et al. Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis. Nature Communications 14(1):2514, 1-16 (2023). [cited by applicant]
Rahim, Maha K. et al. Dynamic CD8+ T Cell Responses to Cancer Immunotherapy in Human Regional Lymph Nodes Are Disrupted in Metastatic Lymph Nodes. Cell 186(6):1127-1143 (2023). [cited by applicant]
Ramirez, Delaney E., and Mary Jo Turk. Th1-like Treg Cells Are Dressed to Suppress Anti-tumor Immunity. Immunity 56(7):1437-1439 (2023). [cited by applicant]
Rapp, Moritz. et al. CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. The Journal of experimental medicine 216(5):1170-1181 (2019). [cited by applicant]
Ratcliffe, Peter J. HIF-1 and HIF-2: Working Alone or Together in Hypoxia ?. The Journal of Clinical Investigation 117(4):862-865 (2007). [cited by applicant]
Roberts et al.: Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell 30:324-336 (2016). [cited by applicant]
Robinson, Mark D. et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. bioinformatics 26(1):139-140 (2010). [cited by applicant]
Roquilly, Antoine. et al. Spatiotemporal adaptations of macrophage and dendritic cell development and function. Annual Review of Immunology 40:525-557 (2022). [cited by applicant]
Rowe, Jared H. et al. Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature 490(7418):102-106 (2012). [cited by applicant]
Ruhland, Megan K. et al. Visualizing Synaptic Transfer of Tumor Antigens Among Dendritic Cells. Cancer Cell 37(6):786-799 (2020). [cited by applicant]
Satpathy et al. Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. J Exp Med 209:1135-1152 (2012). [cited by applicant]
Scandling, John D. et al. Induced Immune Tolerance for Kidney Transplantation. New England Journal of Medicine 365(14):1359-1360 (2011). [cited by applicant]
Scandling, John D. et al. Macrochimerism and clinical transplant tolerance. Human immunology 79(5):266-271 (2018). [cited by applicant]
Scandling, John D. et al. Tolerance and Chimerism After Renal and Hematopoietic-cell Transplantation. The New England Journal of Medicine 358(4):362-368 (2008). [cited by applicant]
Schenkel, Jason M. et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity 54(10):2338-2353.e6 (2021). [cited by applicant]
Schulz, Oliver, and Caetano Reis e Sousa. Cross-presentation of Cell-associated Antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells. Immunology 107(2):183-189 (2002). [cited by applicant]
Schurch, Christian M. et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell 182(5):1341-1359 (2020). [cited by applicant]
Sendoel, Ataman, and Michael O. Hengartner. Apoptotic Cell Death Under Hypoxia. Physiology 29(3):168-176 (2014). [cited by applicant]
Shao, Tzu-Yu. et al. Reproductive outcomes after pregnancy-induced displacement of preexisting microchimeric cells. Science 381(6664):1324-1330 (2023). [cited by applicant]
Siddiqui, Imran et al. Intratumoral Tcf1+ PD-1+ CD8+ T Cells With Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity 50(1):195-211 (2019). [cited by applicant]
Silva-Sanchez, Aaron. et al. Activation of regulatory dendritic cells by Mertk coincides with a temporal wave of apoptosis in neonatal lungs. Science immunology 8(84):eadc9081, 1-35 (2023). [cited by applicant]
Sisirak, Vanja. et al. Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell 166(1):88-101 (2016). [cited by applicant]
Slavin, S. et al. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. Science 193(4259):1252-1254 (1976). [cited by applicant]
Soares, Miguel P., and Iqbal Hamza. Macrophages and iron metabolism. Immunity 44(3):492-504 (2016). [cited by applicant]
Spitzer et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell 168:487-502 (2017). [cited by applicant]
Spranger, Stefani. et al. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31(5):711-723.e4 (2017). [cited by applicant]
Steinman, Ralph M. et al. The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic Cells. The Journal of Experimental Medicine 191(3):411-416 (2000). [cited by applicant]
Subramanian, Aravind. et al. Gene Set Enrichment Analysis: a Knowledge-based Approach for Interpreting Genome-wide Expression Profiles. Proceedings of the National Academy of Sciences of the United States of America 102… [cited by applicant]
Theisen, Derek, and Kenneth Murphy. The Role of cDC1s in Vivo: CD8 T Cell Priming through Cross-presentation. F1000Res 6:98, 1-10 (2017). [cited by applicant]
Thomson, Angus W., and Percy A. Knolle. Antigen-presenting cell function in the tolerogenic liver environment. Nature Reviews Immunology 10(11):753-766 (2010). [cited by applicant]
Thumkeo, Dean. et al. PGE(2)-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell reports 39(10):110914, 1-15 (2022). [cited by applicant]
Tonelli, Marcello. et al. Benefits and Harms of Erythropoiesis-stimulating Agents for Anemia Related to Cancer: A Meta-analysis. CMAJ 180(11):E62-E71 (2009). [cited by applicant]
Travis, Mark A. et al. Loss of integrin alpha-v-beta-8 on dendritic cells causes autoimmunity and colitis in mice. Nature 449(7160):361-365 (2007). [cited by applicant]
Tsai, Peter T. et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. Journal of Neuroscience 26(4):1269-1274 (2006). [cited by applicant]
Ugur, Milas. et al. Lymph node medulla regulates the spatiotemporal unfolding of resident dendritic cell networks. Immunity 56(8):1778-1793. e1-e10 (2023). [cited by applicant]
Vallelian, Florence. et al. Heme-stress activated NRF2 skews fate trajectories of bone marrow cells from dendritic cells towards red pulp-like macrophages in hemolytic anemia. Cell Death Differ 29(8):1450-1465 (2022). [cited by applicant]
Wagener , F. A. et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 98(6):1802-1811 (2001). [cited by applicant]
Wang, Guang L., and Gregg L. Semenza. Purification and characterization of hypoxia-inducible factor 1. Journal of biological chemistry 270(3):1230-1237 (1995). [cited by applicant]
Wang, Qingfei. et al. Understanding and targeting erythroid progenitor cells for effective cancer therapy. Current Opinion in Hematology 30(4):137-143 (2023). [cited by applicant]
Wei, Xu. et al. Erythropoietin protects against murine cerebral malaria through actions on host cellular immunity. Infection and Immunity 82(1):165-173 (2014). [cited by applicant]
Welsch, Thilo. et al. Prognostic significance of erythropoietin in pancreatic adenocarcinoma. PLoS One 6(8):e23151, 1-12 (2011). [cited by applicant]
Wild, Andreas B. et al. CD83 Orchestrates Immunity Toward Self and Non-self in Dendritic Cells. JCI Insight 4(20):e126246, 1-15 (2019). [cited by applicant]
Wohn, Christian. et al. Absence of MHC class II on cDC1 Dendritic Cells Triggers Fatal Autoimmunity to a Cross-presented Self-antigen. Science Immunology 5(45):eaba1896, 1-12 (2020). [cited by applicant]
Wu, Renee. et al. Mechanisms of CD40-dependent cDC1 Licensing Beyond Costimulation. Nature Immunology 23(11):1536-1550 (2022). [cited by applicant]
Wu, Tianzhi. et al. Clusterprofiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data. Innovation 2(3):100141, 1-10 (2021). [cited by applicant]
Wu, Xiaodi. et al. Mafb lineage tracing to distinguish macrophages from other immune lineages reveals dual identity of Langerhans cells. The Journal of experimental medicine 213(12):2553-2565 (2016). [cited by applicant]
Yamazaki, Sayuri et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. The Journal of Immunology 181(10):6923-6933 (2008). [cited by applicant]
Yarchoan, Mark. et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377(25):2500-2501 (2017). [cited by applicant]
Yenyuwadee, Sasitorn. et al. The evolving role of tissue-resident memory T cells in infections and cancer. Science Advances 8(33):eabo5871, 1-16 (2022). [cited by applicant]
Yi, Rulan. et al. Impact of Protein Identity on Tumor-associated Antigen Uptake Into Infiltrating Immune Cells: A Comparison of Different Fluorescent Proteins as Model Antigens. Plos One 17(8):e0272857, 1-12 (2022). [cited by applicant]
Yin, Weiqin. et al. Erythropoietin regulates energy metabolism through EPO-EpoR-RUNX1 axis. Nature communications 15(1):8114, 1-17 (2024). [cited by applicant]
Yuen, Vincent Wai-Hin. et al. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. Journal of Hepatology 78(2):376-389 (2023). [cited by applicant]
Zagorulya, Maria, and Stefani Spranger. Once upon a prime: DCs shape cancer immunity. Trends in cancer 9(2):172-184 (2023). [cited by applicant]
Zagorulya, Maria. et al. Tissue-specific Abundance of Interferon-gamma Drives Regulatory T Cells to Restrain Dc1-mediated Priming of Cytotoxic T Cells Against Lung Cancer. Immunity 56(2):386-405 (2023). [cited by applicant]
Zhang, Huan. et al. EpoR-tdTomato-Cre mice enable identification of EpoR expression in subsets of tissue macrophages and hematopoietic cells. Blood 138(20):1986-1997 (2021). [cited by applicant]
Zhang, Qiming. et al. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell 179(4):829-845 (2019). [cited by applicant]
Zheng, Liangtao. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374(6574):eabe6474, (2021). [cited by applicant]
Zhu, Qin. et al. deMULTIplex2: robust sample demultiplexing for scRNA-seq. Genome biology 25(1):37, 1-24 (2024). [cited by applicant]
Zundel, Wayne. et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes and development 14(4):391-396 (2000). [cited by applicant]
Harris, Kevin W. Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in [cited by applicant]
Johnson, Dana L. et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 37(11):3699-3710 (1998). [cited by applicant]
McKinney, Matthew, and Murat O. Arcasoy. Erythropoietin for oncology supportive care. Experimental cell research 317(9):1246-1254 (2011). [cited by applicant]
Middleton, Steven A. et al. Identification of a critical ligand binding determinant of the human erythropoietin receptor evidence for common ligand binding motifs in the cytokine receptor family. Journal of biological c… [cited by applicant]
Wrighton, Nicholas C. et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273(5274):458-463 (1996). [cited by applicant]
Chiu et al.: Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity. Science 388:376 (2025). [cited by applicant]
U.S. Appl. No. 18/844,732 Notice of Allowance dated Aug. 12, 2025. [cited by applicant]